3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
8
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Salivary Gland Neoplasms
1
Refractory or Relapsed Solid Tumors
1
Prostatic Neoplasms, Castration-Resistant
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Bulbo-Spinal Atrophy, X-Linked
1
Biochemically Recurrent Prostate Cancer
1
Adenocarcinoma
1
Interventions
Specimen Handling
4
Biopsy
4
Whole-Body Irradiation
3
Mycophenolic Acid
3
Cyclosporine
3
Cyclophosphamide
3
fludarabine phosphate
2
decitabine and cedazuridine drug combination
2
Sirolimus
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Busulfan
2
venetoclax
1
tocilizumab
1
ruxolitinib
1
peginterferon alfa-2b
1
iadademstat
1
fludarabine
1
Tacrolimus
1
Rituximab
1
Peripheral Blood Stem Cell Transplantation
1
Methotrexate
1
Idarubicin
1
Hyperbaric Oxygenation
1
Filgrastim
1
Etoposide
1
Cytarabine
1
Cyclosporins
1
Cord Blood Stem Cell Transplantation
1
Clofarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
darolutamide
×
30 days
×
Clear all
No trials found.